Welcome to our dedicated page for Zhengye Biotechnology Holding news (Ticker: ZYBT), a resource for investors and traders seeking the latest updates and insights on Zhengye Biotechnology Holding stock.
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) is a veterinary vaccine manufacturer that combines research, development, manufacturing, and sales of vaccines for animals. Through its operating entity in Jilin, China, the company focuses on livestock vaccines and also develops products for other animals, including dogs, with distribution across many provincial regions in China and exports to Vietnam, Pakistan, and Egypt.
This news page aggregates coverage of ZYBT stock and corporate announcements so readers can follow how Zhengye Biotechnology’s business evolves. Company news often highlights financial results, revenue mix across swine, poultry, and other vaccines, and management’s commentary on market conditions and customer diversification. For example, the company has discussed reducing sales to its largest swine vaccine customer to lower concentration risk and has described fiscal periods as transformational when strategic shifts are implemented.
Investors can also find updates on research and development, such as progress in China’s pet vaccine market and clinical trials for vaccines targeting cats and dogs. Another recurring theme in Zhengye’s news is regulatory and scientific recognition, including approvals from the Ministry of Agriculture and Rural Affairs for Category I New Veterinary Drugs jointly developed with partner institutions.
In addition, news items cover capital markets events such as the pricing, closing, and over-allotment exercise of the company’s initial public offering on the Nasdaq Capital Market, as well as notices from NASDAQ regarding listing compliance matters. By reviewing this news feed, readers can track Zhengye Biotechnology’s operational performance, strategic priorities, R&D milestones, and listing-related developments over time.
Zhengye Biotechnology (Nasdaq: ZYBT) implemented a dual-class share structure effective April 7, 2026, following shareholder approval on March 24, 2026.
The authorized capital was reclassified to 2,000,000,000 ordinary shares (1,900,000,000 Class A; 100,000,000 Class B). Class A carries one vote; Class B carries twenty votes and is convertible into Class A at holder option. Amended governance documents were filed and are effective.
Zhengye Biotechnology (Nasdaq: ZYBT) reported 2025 R&D, regulatory, production and commercial milestones and outlined 2026 strategic priorities. Key 2025 achievements include 4 patent grants, 10 patent filings, 2 National Category I and 1 Category III veterinary drug approvals, 7 new product licenses, eight registration projects under review, RMB800,000 government funding for a provincial innovation center, and listing on Nasdaq in January 2025. International progress included Pakistan approvals on Jan 16, 2026 and submissions to Egypt and Vietnam. 2026 priorities target large customers, product-led solutions (PCV2/PCV3), companion animal M&A, laboratory network expansion, and digitalized manufacturing.
Zhengye Biotechnology (NASDAQ:ZYBT), a Chinese veterinary vaccine manufacturer, reported its fiscal year 2024 results showing a strategic shift in operations. Net revenues decreased 12% to RMB186.4 million (US$25.5M), while net income fell to RMB13.5 million (US$1.8M) from RMB37.5 million in 2023.
The company made significant progress in R&D, receiving two Category I New Veterinary Drug Certificates from China's Ministry of Agriculture and Rural Affairs. Zhengye completed clinical trials for cat and dog vaccines, marking its expansion into the pet vaccine market. The company also successfully completed its IPO on January 8, 2025, raising $6.9 million through the issuance of 1.725 million shares at $4.00 per share.
Strategic decisions included reducing swine vaccine sales to diversify customer base and minimize concentration risk, despite causing short-term revenue decline. The company maintained strong R&D investments and plans to expand globally following its Nasdaq listing.
Zhengye Biotechnology (NASDAQ: ZYBT), a Chinese veterinary vaccine manufacturer, has received a delinquency notice from NASDAQ on May 20, 2025, due to failing to file its 2024 annual report (Form 20-F) on time. The company has 60 calendar days to submit a compliance plan to NASDAQ. If accepted, NASDAQ may grant an extension of up to 180 calendar days until November 11, 2025, to regain compliance. The notice does not immediately affect ZYBT's listing status on the Nasdaq Capital Market.
Zhengye Biotechnology Holding (ZYBT), a Chinese veterinary vaccine manufacturer, announced that underwriters have fully exercised their over-allotment option to purchase an additional 225,000 ordinary shares at $4.00 per share. This follows the company's initial public offering on the Nasdaq Capital Market, which began trading on January 7, 2025.
The total gross proceeds from the IPO, including the over-allotment exercise, amounted to $6.9 million before deducting underwriting discounts and expenses. The company plans to use the proceeds for acquiring vaccine production companies and R&D projects. Kingswood Capital Partners served as the sole book-running manager for the offering.
Zhengye Biotechnology (Nasdaq: ZYBT), a Chinese veterinary vaccine manufacturer, has announced the closing of its Initial Public Offering. The company successfully offered 1,500,000 ordinary shares at $4.00 per share, raising gross proceeds of $6 million. Trading commenced on January 7, 2025, on the Nasdaq Capital Market under the symbol 'ZYBT'.
The company has granted the underwriter a 45-day option to purchase up to an additional 225,000 ordinary shares to cover potential over-allotments. The IPO proceeds will be allocated towards acquiring vaccine production companies and conducting R&D projects. Kingswood Capital Partners served as the sole book-running manager for the offering.
Zhengye Biotechnology, a Chinese veterinary vaccine manufacturer, has announced the pricing of its initial public offering (IPO) on the Nasdaq Capital Market. The company is offering 1,500,000 ordinary shares at $4.00 per share, expecting to raise $6 million in gross proceeds before expenses.
Trading will commence on January 7, 2025, under the ticker symbol ZYBT. The offering is expected to close around January 8, 2025. Underwriters have a 45-day option to purchase up to additional 225,000 shares to cover over-allotments. The proceeds will be used for acquiring vaccine production companies and R&D projects.
Kingswood Capital Partners is serving as the sole book-running manager for this offering.